GSE	Species	PMID	Paper	Title	CellType	Tissue	Disease	Cell_Pop	Release_Date	Last_Update_Date	GSMs	Cell_Line	fields_dataType	Key_Match
GSE195471	Homo sapiens	None	None	Pembrolizumab and decitabine for refractory or relapsed acute myeloid leukemia	None	None	None	None	2022-01-26	2022-01-26	SRX13932590; SRX13932591; SRX13932592; SRX13932593; SRX13932594; SRX13932595; SRX13932596; SRX13932597; SRX13932598; SRX13932599; SRX13932600; SRX13932601; SRX13932602; SRX13932603; SRX13932604; SRX13932621; SRX13932622; SRX13932623; SRX13932624; SRX13932625; SRX13932626; SRX13932627; SRX13932628; SRX13932629; SRX13932630; SRX13932631; SRX13932632; SRX13932633; SRX13932634; SRX13932635; SRX13932636; SRX13932605; SRX13932606; SRX13932607; SRX13932608; SRX13932609; SRX13932610; SRX13932611; SRX13932612; SRX13932613; SRX13932614; SRX13932615; SRX13932616; SRX13932617; SRX13932618; SRX13932619; SRX13932620; SRX13932637	None	GSM5837980; GSM5837995; GSM5838019; GSM5837999; GSM5837978; GSM5837984; GSM5837986; GSM5838008; GSM5838006; GSM5837992; GSM5837983; GSM5837982; GSM5837988; GSM5838014; GSM5838005; GSM5838001; GSM5837991; GSM5838022; GSM5837996; GSM5838010; GSM5838002; GSM5837998; GSM5838009; GSM5838017; GSM5837977; GSM5837993; GSM5838012; GSM5838018; GSM5838007; GSM5838011; GSM5837979; GSM5838003; GSM5838004; GSM5838016; GSM5838020; GSM5838015; GSM5837987; GSM5838023; GSM5837981; GSM5838013; GSM5837994; GSM5837989; GSM5837990; GSM5838000; GSM5837997; GSM5837985; GSM5838024; GSM5838021	{'Series/Title': 'Pembrolizumab and decitabine for refractory or relapsed acute myeloid leukemia', 'Series/Summary': 'Background: The powerful ‘graft versus leukemia’ effect thought partly responsible for the therapeutic effect of allogeneic hematopoietic cell transplantation in acute myeloid leukemia (AML) provides rationale for investigation of immune-based therapies in this high-risk blood cancer. There is considerable preclinical evidence for potential synergy between PD-1 immune checkpoint blockade and the hypomethylating agents already commonly used for this disease. Methods: We report here the results of 17 H-0026 (PD- AML, NCT02996474), an investigator sponsored, single- institution, single-arm open-label 10-subject pilot study to test the feasibility of the first-in-human combination of pembrolizumab and decitabine in adult patients with refractory or relapsed AML (R-AML). Results: In this cohort of previously treated patients, this novel combination of anti-PD-1 and hypomethylating therapy was feasible and associated with a best response of stable disease or better in 6 of 10 patients. Considerable immunological changes were identified using T cell receptor β sequencing as well as single-cell immunophenotypic and RNA expression analyses on sorted CD3+ T cells in patients who developed immune- related adverse events (irAEs) during treatment. Clonal T cell expansions occurred at irAE onset; single-cell sequencing demonstrated that these expanded clones were predominately CD8+ effector memory T cells with high cell surface PD-1 expression and transcriptional profiles indicative of activation and cytotoxicity. In contrast, no such distinctive immune changes were detectable in those experiencing a measurable antileukemic response during treatment. Conclusion: Addition of pembrolizumab to 10-day decitabine therapy was clinically feasible in patients with R-AML, with immunological changes from PD-1 blockade observed in patients experiencing irAEs.', 'Series/Type': 'Expression profiling by high throughput sequencing; Other', 'Series/Overall-Design': "48 samples are analyzed. 8 samples are for 2 patients at day 0 and relapse time point using 10x Genomics 3' with both gene expression and protein libraries. The same two patients have samples for MissionBio at relapse time point with DNA and protein . 10x Genomics 5' experiments are performed for 4 patients at 3 different time points with gene expression, protein and VDJ libraries.", 'Series/Status/Release-Date': '2022-01-26', 'Series/Status/Last-Update-Date': '2022-01-26', 'Series/Pubmed-ID': '35017151', 'Sample/Channel/Characteristics': 'pembrolizumab and decitabine      ; pembrolizumab and decitabine      ; pembrolizumab and decitabine      ; pembrolizumab and decitabine      ; pembrolizumab and decitabine      ; pembrolizumab and decitabine      ; pembrolizumab and decitabine      ; pembrolizumab and decitabine      ; pembrolizumab and decitabine      ; pembrolizumab and decitabine      ; pembrolizumab and decitabine      ; pembrolizumab and decitabine      ; pembrolizumab and decitabine      ; pembrolizumab and decitabine      ; pembrolizumab and decitabine      ; pembrolizumab and decitabine      ; pembrolizumab and decitabine      ; pembrolizumab and decitabine      ; pembrolizumab and decitabine      ; pembrolizumab and decitabine      ; pembrolizumab and decitabine      ; pembrolizumab and decitabine      ; pembrolizumab and decitabine      ; pembrolizumab and decitabine      ; pembrolizumab and decitabine      ; pembrolizumab and decitabine      ; pembrolizumab and decitabine      ; pembrolizumab and decitabine      ; pembrolizumab and decitabine      ; pembrolizumab and decitabine      ; pembrolizumab and decitabine      ; pembrolizumab and decitabine      ; pembrolizumab and decitabine      ; pembrolizumab and decitabine      ; pembrolizumab and decitabine      ; pembrolizumab and decitabine      ; pembrolizumab and decitabine      ; pembrolizumab and decitabine      ; pembrolizumab and decitabine      ; pembrolizumab and decitabine      ; pembrolizumab and decitabine      ; pembrolizumab and decitabine      ; pembrolizumab and decitabine      ; pembrolizumab and decitabine      ; pembrolizumab and decitabine      ; pembrolizumab and decitabine      ; pembrolizumab and decitabine      ; pembrolizumab and decitabine      ', 'Sample/Relation': 'SRX13932590; SRX13932591; SRX13932592; SRX13932593; SRX13932594; SRX13932595; SRX13932596; SRX13932597; SRX13932598; SRX13932599; SRX13932600; SRX13932601; SRX13932602; SRX13932603; SRX13932604; SRX13932621; SRX13932622; SRX13932623; SRX13932624; SRX13932625; SRX13932626; SRX13932627; SRX13932628; SRX13932629; SRX13932630; SRX13932631; SRX13932632; SRX13932633; SRX13932634; SRX13932635; SRX13932636; SRX13932605; SRX13932606; SRX13932607; SRX13932608; SRX13932609; SRX13932610; SRX13932611; SRX13932612; SRX13932613; SRX13932614; SRX13932615; SRX13932616; SRX13932617; SRX13932618; SRX13932619; SRX13932620; SRX13932637'}	{'match_res0': {'Series/Title0': ['leukemia'], 'Series/Summary0': ['leukemia']}, 'match_res1': {'Series/Summary1': ['PD1']}, 'match_res2': {}}
